Endothelial Cell Dysfunction in Allogeneic Stem Cell Transplantation Outcomes
Overview
Endothelial cell (EC) dysfunction plays a pivotal role in the development of severe complications following allogeneic stem cell transplantation (alloSCT), including sinusoidal obstruction syndrome/venoocclusive disease (SOS/VOD), transplant-associated thrombotic microangiopathy (TA-TMA), and refractory acute graft-versus-host disease (aGVHD). Biomarkers of endothelial injury are critical for diagnosis, prognostication, and guiding targeted therapies in these syndromes.
Background
The vascular endothelium is a dynamic organ regulating vascular tone, coagulation, and inflammatory responses. During alloSCT, ECs are exposed to multiple insults from conditioning regimens, immunosuppressive drugs, inflammatory mediators, and alloreactive immune responses. This leads to EC activation and injury, which may progress to endothelial dysfunction manifesting as clinically significant syndromes such as SOS/VOD, TA-TMA, and refractory aGVHD. Patient-specific factors including pre-existing endothelial damage and genetic predispositions influence individual vulnerability to these complications.
Data Highlights
Endothelial Injury Syndrome
Incidence/Prevalence
Mortality Rate
Key Biomarkers
SOS/VOD
Not specified
Variable
Markers summarized in Table 1 (e.g., endothelial activation markers)
TA-TMA
Up to 25-30% of alloSCT patients
Up to 90% in severe forms
Complement dysregulation markers, endothelial injury biomarkers (see Table 1)
Refractory aGVHD
Not specified
Major cause of mortality
ANG2, ST2, ICAM-1, VCAM-1, vWF, thrombomodulin
Key Findings
Endothelial cells are central mediators and targets in alloSCT-related complications due to their role in vascular homeostasis and immune responses.
EC injury syndromes such as SOS/VOD, TA-TMA, and refractory aGVHD are associated with high morbidity and mortality post-alloSCT.
Biomarkers including ANG2, ST2, and markers of complement activation are valuable for early diagnosis and risk stratification of endothelial complications.
Functional heterogeneity of ECs across tissues contributes to variable clinical presentations and complicates the establishment of uniform diagnostic criteria.
Targeted therapies, such as terminal complement blockade, show promise in managing high-risk TA-TMA patients identified by biomarker algorithms.
Clinical Implications
Recognition of endothelial dysfunction as a key driver of alloSCT complications underscores the importance of monitoring endothelial biomarkers for early detection and intervention. Personalized approaches considering patient-specific endothelial vulnerability and biomarker profiles may improve outcomes by guiding targeted therapies. Awareness of EC functional heterogeneity is essential when interpreting diagnostic tests and managing endothelial injury syndromes.
Conclusion
Endothelial cell dysfunction is a crucial factor influencing the development and severity of post-alloSCT complications. Integrating biomarker assessment with clinical management can enhance diagnosis, prognostication, and treatment of endothelial injury syndromes, ultimately improving patient outcomes.
References
Schmidt et al. 2023 -- Endothelial Cell Dysfunction: A Crucial Factor Influencing Outcomes in Allogeneic Stem Cell Transplantation
